Evaxion Biotech A/S
NASDAQ: EVAX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Helen Katrina Tayton-Martin
- Employees
- 46
- Headquarters
- Horsholm, Denmark
- IPO year
- 2021
- Market cap
- $21.4M
- Website
- https://www.evaxion-biotech.com
Loading EVAX…
Loading profile data…Frequently asked questions about EVAX
What does Evaxion Biotech A/S (EVAX) do?
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb c...
Where does EVAX trade?
Evaxion Biotech A/S (EVAX) trades on the NASDAQ Capital Market.
What sector is EVAX in?
Evaxion Biotech A/S (EVAX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Evaxion Biotech A/S?
Helen Katrina Tayton-Martin is the chief executive officer of Evaxion Biotech A/S (EVAX).
Where is Evaxion Biotech A/S headquartered?
Evaxion Biotech A/S is headquartered in Denmark.
Does EVAX pay a dividend?
Evaxion Biotech A/S (EVAX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EVAX go public?
Evaxion Biotech A/S (EVAX) completed its initial public offering in 2021.
Is EVAX an ADR?
Yes — EVAX is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Evaxion Biotech A/S reporting and dividends follow the underlying issuer.